

KPL-404

Phase 1



Mechanism of Action

Monoclonal antibody inhibitor of CD40 signaling. KPL-404 is designed to inhibit CD40-CD40L interaction, a key T-cell costimulatory pathway critical for B-cell maturation and immunoglobulin class switching.

Rationale

CD40-CD40L interaction is an attractive target for blocking T-cell-mediated B-cell-driven autoimmunity and prevention of solid organ transplant rejection. External proof-of-concept for inhibition of this pathway has been previously established in patients with a broad range of autoimmune diseases, including rheumatoid arthritis, Sjögren's syndrome, Graves' disease, systemic lupus erythematosus and solid organ transplant.

Status: Phase 1

We are enrolling healthy subjects in a single-ascending-dose Phase 1 clinical trial. The first-in-human trial will provide safety data and pharmacokinetics as well as receptor occupancy and T-cell Dependent Antibody Responses. Data are expected in the fourth quarter of 2020.

